Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
出版年份 2018 全文链接
标题
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
作者
关键词
-
出版物
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-12-03
DOI
10.1002/cpt.1321
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Value of the CHA2DS2-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation
- (2018) Dan Liu et al. Clinical Research in Cardiology
- Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy
- (2018) Jonas Müntze et al. EUROPEAN HEART JOURNAL
- Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T
- (2018) Daniel Oder et al. MEDICINE
- Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease
- (2017) M. Lenders et al. JOURNAL OF INTERNAL MEDICINE
- α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry DiseaseCLINICAL PERSPECTIVE
- (2017) Daniel Oder et al. Circulation-Cardiovascular Genetics
- The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
- (2016) Elfrida R. Benjamin et al. GENETICS IN MEDICINE
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
- (2016) Derralynn A Hughes et al. JOURNAL OF MEDICAL GENETICS
- Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
- (2016) Dominique P. Germain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y
- (2016) Daniel Oder et al. BMJ Open
- High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
- (2016) Nora Seydelmann et al. Journal of the American Heart Association
- Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease
- (2015) Jan Lukas et al. HUMAN MUTATION
- Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
- (2015) M. Lenders et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
- (2015) Christoph Kampmann et al. Orphanet Journal of Rare Diseases
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
- (2015) Roberto M. Lang et al. European Heart Journal-Cardiovascular Imaging
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- Potential role of vitamin D deficiency on Fabry cardiomyopathy
- (2013) Christiane Drechsler et al. JOURNAL OF INHERITED METABOLIC DISEASE
- A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects
- (2013) R. Giugliani et al. MOLECULAR GENETICS AND METABOLISM
- Role of Serum N-Terminal Pro-Brain Natriuretic Peptide Measurement in Diagnosis of Cardiac Involvement in Patients With Anderson-Fabry Disease
- (2012) Caroline J. Coats et al. AMERICAN JOURNAL OF CARDIOLOGY
- Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
- (2012) Dominique P Germain et al. Orphanet Journal of Rare Diseases
- A pharmacogenetic approach to identify mutant forms of α-galactosidase a that respond to a pharmacological chaperone for Fabry disease
- (2011) Xiaoyang Wu et al. HUMAN MUTATION
- Rapid Exclusion of Acute Myocardial Infarction in Patients With Undetectable Troponin Using a High-Sensitivity Assay
- (2011) Richard Body et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Fabry disease
- (2010) Dominique P Germain Orphanet Journal of Rare Diseases
- The pharmacological chaperone 1-deoxygalactonojirimycin increases α-galactosidase A levels in Fabry patient cell lines
- (2009) E. R. Benjamin et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data
- (2009) A Mehta et al. LANCET
- Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
- (2009) R. Schiffmann et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy
- (2008) A. Ortiz et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Elevated globotriaosylsphingosine is a hallmark of Fabry disease
- (2008) J. M. Aerts et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now